A potential health concern has emerged with the new Ozempic and Wegovy pills, which contain a hidden ingredient that may have unexpected side effects.
The Quest for Weight Loss: A Controversial Journey?
The recent introduction of GLP-1 drugs in pill form has brought a new dimension to weight loss treatments. However, there's a catch: a compound called salcaprozate sodium (SNAC) is used to ensure the active ingredient, semaglutide, survives in the stomach and reaches the bloodstream. But here's where it gets controversial: this compound might come with some unwanted baggage.
Historically, semaglutide, the key component in Ozempic and Wegovy, has been administered via weekly injections into the fatty tissue beneath the skin. To overcome consumer aversion to needles, manufacturers developed a daily pill. Novo Nordisk launched the Wegovy pill in January, with the Ozempic pill expected soon after.
The Pill's Promise and Potential Pitfalls
While injections deliver the drug directly into the bloodstream, the pill's effectiveness relies on SNAC. Researchers from the University of Adelaide studied the impact of repeated SNAC exposure on gut microbiota, metabolic function, and related health markers using animal models.
Lead author Amin Ariaee, a PhD candidate at Adelaide University, emphasized the need to understand the long-term effects of all pill ingredients, not just the active drug, as oral versions become more popular.
In a 21-day study, the team observed several changes:
- A decrease in good gut bacteria that breaks down dietary fiber
- Lower levels of short-chain fatty acids, which are crucial for intestinal barrier strength, inflammation reduction, and immune system function
- Increased inflammatory markers in the blood
- Higher liver weight
- A smaller cecum, a part of the large intestine where gut bacteria breaks down fiber and produces protective compounds
- Lower levels of a protein associated with cognitive impairment
Ariaee highlights that while the pill offers convenience, it may also lead to shifts in potentially harmful gut bacteria, elevated inflammation, and depletion of proteins linked to cognitive function.
He emphasizes that while the study doesn't prove SNAC is inherently harmful to humans, it does suggest that the compound affects the body beyond its role in facilitating semaglutide's function, warranting further investigation.
The Future of GLP-1 Treatments
Novo Nordisk's semaglutide pill is already on the market, and Lilly's daily pill, Orforglipron, is expected to receive FDA approval this spring. While these pills offer gastrointestinal side effects and less dramatic results than injectables, drugmakers believe their potential is significant.
The pills' convenience and cost-effectiveness compared to injections make understanding the long-term effects of SNAC exposure crucial.
Dr. Paul Joyce, Senior Research Fellow, underscores the importance of evaluating all components of these therapies, especially as their global use expands.
So, while these pills offer an attractive alternative to injections, the question remains: are we trading one set of challenges for another? What are your thoughts on this potential trade-off? Feel free to share your opinions in the comments below!
